Comparison of Infliximab and Adalimumab in Biologic-Naive Patients With Ulcerative Colitis: A Nationwide Danish Cohort Study

Clinical Gastroenterology and Hepatology

Volumn 15, Issue 8, 2017, Pages 1218-1225.e7

  Singh, Siddharth ^a   Andersen, Nynne Nyboe ^b   Andersson, Mikael ^b   Loftus, Edward V ^c   Jess, Tine ^b,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b STATENS SERUM INSTITUT   (Denmark)

^c MAYO CLINIC   (United States)

^d The Capital Region   (Denmark)

Author keywords

Biologics; Comparative Effectiveness; Inflammatory Bowel Disease; Propensity Matching

Indexed keywords

ADALIMUMAB; INFLIXIMAB; ANTIINFLAMMATORY AGENT;

ABDOMINAL SURGERY; ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL FEATURE; COHORT ANALYSIS; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DANISH CITIZEN; DENMARK; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG SAFETY; FEMALE; HEALTH CARE PERSONNEL; HEALTH CARE UTILIZATION; HOSPITALIZATION; HUMAN; IMMUNOMODULATION; INFECTION; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; SURGICAL RISK; TOTAL QUALITY MANAGEMENT; ULCERATIVE COLITIS; COMMUNICABLE DISEASE; COMPARATIVE STUDY; MIDDLE AGED; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADALIMUMAB; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS; COHORT STUDIES; COLITIS, ULCERATIVE; COMMUNICABLE DISEASES; DENMARK; FEMALE; HOSPITALIZATION; HUMANS; INFLIXIMAB; MALE; MIDDLE AGED; TREATMENT OUTCOME; YOUNG ADULT;

EID: 85015894787     PISSN: 15423565     EISSN: 15427714     Source Type: Journal    
DOI: 10.1016/j.cgh.2016.11.024     Document Type: Article

References (29)

1. Nielsen, O.H., Ainsworth, M.A., Tumor necrosis factor inhibitors for inflammatory bowel disease. N Engl J Med 369 (2013), 754–762.
2. Kornbluth, A., Sachar, D.B., Practice Parameters Committee of the American College of G. Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 105 (2010), 501–523.
3. Sandborn, W.J., Rutgeerts, P., Feagan, B.G., et al. Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. Gastroenterology 137 (2009), 1250–1260.
4. Feagan, B.G., Sandborn, W.J., Lazar, A., et al. Adalimumab therapy is associated with reduced risk of hospitalization in patients with ulcerative colitis. Gastroenterology 146 (2014), 110–118.
5. Nestorov, I., Clinical pharmacokinetics of TNF antagonists: how do they differ?. Semin Arthritis Rheum 34:Suppl 1 (2005), 12–18.
6. Danese, S., Fiorino, G., Peyrin-Biroulet, L., et al. Biological agents for moderately to severely active ulcerative colitis: a systematic review and network meta-analysis. Ann Intern Med 160 (2014), 704–711.
7. Singh, S., Garg, S.K., Wang, Z., et al. Letter: comparative efficacy of biological therapy in patients with ulcerative colitis. Aliment Pharmacol Ther 39 (2014), 1432–1433.
8. Singh, S., Heien, H.C., Sangaralingham, L.R., et al. Comparative effectiveness and safety of infliximab and adalimumab in patients with ulcerative colitis. Aliment Pharmacol Ther 43 (2016), 994–1003.
9. Sandborn, W.J., Sakuraba, A., Wang, A., et al. Comparison of real-world outcomes of adalimumab and infliximab for patients with ulcerative colitis in the United States. Curr Med Res Opin 32 (2016), 1233–1241.
10. Pedersen, C.B., Gotzsche, H., Moller, J.O., et al. The Danish Civil Registration System. A cohort of eight million persons. Dan Med Bull 53 (2006), 441–449.
11. Andersen, T.F., Madsen, M., Jorgensen, J., et al. The Danish National Hospital Register. A valuable source of data for modern health sciences. Dan Med Bull 46 (1999), 263–268.
12. Fonager, K., Sorensen, H.T., Rasmussen, S.N., et al. Assessment of the diagnoses of Crohn's disease and ulcerative colitis in a Danish hospital information system. Scand J Gastroenterol 31 (1996), 154–159.
13. Rungoe, C., Langholz, E., Andersson, M., et al. Changes in medical treatment and surgery rates in inflammatory bowel disease: a nationwide cohort study 1979–2011. Gut 63 (2014), 1607–1616.
14. Nyboe Andersen, N., Pasternak, B., Friis-Moller, N., et al. Association between tumour necrosis factor-alpha inhibitors and risk of serious infections in people with inflammatory bowel disease: nationwide Danish cohort study. BMJ, 350, 2015, h2809.
15. Beaugerie, L., Seksik, P., Nion-Larmurier, I., et al. Predictors of Crohn's disease. Gastroenterology 130 (2006), 650–656.
16. Singh, S., Heien, H.C., Sangaralingham, L.R., et al. Comparative effectiveness and safety of anti-tumor necrosis factor agents in biologic-naive patients with Crohn's disease. Clin Gastroenterol Hepatol 14 (2016), 994–1003.
17. Rassen, J.A., Shelat, A.A., Myers, J., et al. One-to-many propensity score matching in cohort studies. Pharmacoepidemiol Drug Saf 21:Suppl 2 (2012), 69–80.
18. Deyo, R.A., Cherkin, D.C., Ciol, M.A., Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 45 (1992), 613–619.
19. Schneeweiss, S., Sensitivity analysis and external adjustment for unmeasured confounders in epidemiologic database studies of therapeutics. Pharmacoepidemiol Drug Saf 15 (2006), 291–303.
20. Laharie, D., Bourreille, A., Branche, J., et al. Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial. Lancet 380 (2012), 1909–1915.
21. Osterman, M.T., Haynes, K., Delzell, E., et al. Comparative effectiveness of infliximab and adalimumab for Crohn's disease. Clin Gastroenterol Hepatol 12 (2014), 811–817.
22. Dotan, I., Ron, Y., Yanai, H., et al. Patient factors that increase infliximab clearance and shorten half-life in inflammatory bowel disease: a population pharmacokinetic study. Inflamm Bowel Dis 20 (2014), 2247–2259.
23. Sharma, S., Eckert, D., Hyams, J.S., et al. Pharmacokinetics and exposure-efficacy relationship of adalimumab in pediatric patients with moderate to severe Crohn's disease: results from a randomized, multicenter, phase-3 study. Inflamm Bowel Dis 21 (2015), 783–792.
24. Bultman, E., de Haar, C., van Liere-Baron, A., et al. Predictors of dose escalation of adalimumab in a prospective cohort of Crohn's disease patients. Aliment Pharmacol Ther 35 (2012), 335–341.
25. Seminerio, J.L., Koutroubakis, I.E., Ramos-Rivers, C., et al. Impact of obesity on the management and clinical course of patients with inflammatory bowel disease. Inflamm Bowel Dis 21 (2015), 2857–2863.
26. Flores, A., Burstein, E., Cipher, D.J., et al. Obesity in inflammatory bowel disease: a marker of less severe disease. Dig Dis Sci 60 (2015), 2436–2445.
27. Stabroth-Akil, D., Leifeld, L., Pfutzer, R., et al. The effect of body weight on the severity and clinical course of ulcerative colitis. Int J Colorectal Dis 30 (2015), 237–242.
28. Bhalme, M., Sharma, A., Keld, R., et al. Does weight-adjusted anti-tumour necrosis factor treatment favour obese patients with Crohn's disease?. Eur J Gastroenterol Hepatol 25 (2013), 543–549.
29. Andersen, N.N., Jess, T., Risk of infections associated with biological treatment in inflammatory bowel disease. World J Gastroenterol 20 (2014), 16014–16019.